Barclays Maintains Overweight on AbbVie, Raises Price Target to $300

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $275 to $300.